BAMBROVA Trademark

Trademark Overview

On Thursday, March 28, 2024, a trademark application was filed for BAMBROVA with the United States Patent and Trademark Office. The USPTO has given the BAMBROVA trademark a serial number of 98472326. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, January 14, 2025. This trademark is owned by Bristol-Myers Squibb Company. The BAMBROVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
bambrova

General Information

Serial Number98472326
Word MarkBAMBROVA
Filing DateThursday, March 28, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateTuesday, January 14, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical and biological preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use, namely, for the treatment of neuropsychiatric disorders; Pharmaceutical preparations for human use, namely, therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors, diagnostic radiopharmaceutical preparations, diagnostic agents, preparations and substances for medical purposes; Pharmaceutical preparations for human use, namely, radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer, radio-isotope markers for therapeutic or diagnostic use.
Translation of Words in MarkThe wording BAMBROVA has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 28, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events

Event DateEvent Description
Thursday, March 28, 2024NEW APPLICATION ENTERED
Thursday, August 29, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 8, 2024ASSIGNED TO EXAMINER
Wednesday, October 16, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 14, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 14, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 14, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 16, 2024NON-FINAL ACTION WRITTEN
Wednesday, October 16, 2024NON-FINAL ACTION E-MAILED

Related Keywords

bambrova diseases pharmaceutical human preparations anti system disease cancer disorders namely